FT Options’s Ligand Pharmaceuticals LGND Stock Holding History

FT Options’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-32,060	Closed	-$26K	–	237
2017 Q1	$26K	Buy	+32,060	New	+$2.11M	0.03%	190
2016 Q3	–	Sell	-32,060	Closed	-$189K	–	419
2016 Q2	$189K	Sell	32,060 -8,015	-20%	-$595K	0.16%	108
2016 Q1	$85K	Buy	+40,075	New	+$2.44M	0.09%	134

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

FT Options's LGND Position: Q2 2017 in Review

FT Options sold out of Ligand Pharmaceuticals (LGND) in Q2 2017, closing a stake of 5,740 shares — an estimated $379K sold.

FT Options first reported a position in LGND in Q1 2016 and held it in 3 quarters. The position peaked at $1.01M in Q2 2016. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2017.

FT Options reported no remaining Ligand Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
FT Options sold 5,740 Ligand Pharmaceuticals shares in Q2 2017, an estimated $379K.
FT Options first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 3 quarters.
FT Options's Ligand Pharmaceuticals position peaked at $1.01M in Q2 2016.
265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2017.

Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.